Head-to-head · WeighScore
Care Bare Rx vs Omada Health
The verdict
Care Bare Rx takes it — 75/100 to 55.6/100.
Care Bare Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Oral as well as injectable routes for both molecules plus a brand Ozempic lane, bundled with hair, TRT and sexual health.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Care Bare Rx | Omada Health |
|---|---|---|
| WeighScore | 75/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #43 | #435 |
| Semaglutide | From $199/mo (shared weight-loss price) | Not disclosed |
| Tirzepatide | From $199/mo (shared weight-loss price) | Not disclosed |
| Coverage | Multi-state | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #43 · C
Strengths
- Oral tirzepatide as well as injectable — rare on this board
- Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
- LegitScript certified and HIPAA compliant
- One platform if you also want hair, TRT, sexual health or NAD+
Where it loses points
- The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
- Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
- No named clinicians, founding year or parent company disclosed
- Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.